Gene-editing company Metagenomi announced a workforce reduction of roughly 25% and leadership departures, including its CEO, as the firm reorients toward a preclinical hemophilia A program. The reorganization follows a year of integration after a merger and comes with a narrower R&D focus aimed at advancing one lead program to IND readiness. Company statements and industry reports indicate the moves are intended to conserve cash and accelerate candidate development in a prioritized area. Observers warned that the cuts may slow broader platform development while concentrating resources on the hemophilia asset. Investors and partners will monitor upcoming preclinical readouts and whether the refocus preserves the underlying gene-editing platform’s strategic value.